Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Journal of Medicinal Chemistry
|
January 10, 2024
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS<sup>G12D</sup>
Chuan Zhou, Zisheng Fan, Yuejiao Gu, et al.
Journal of Medicinal Chemistry
|
February 21, 2012
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant
Shaohua Chang, Lianwen Zhang, Shilin Xu, et al.
Journal of the American Chemical Society
|
June 4, 2026
Glycoengineered Host-Guest Nanoparticles Potentiate Alzheimer's Disease Therapy via Lesion-Specific Modulation of Tau Pathology
Yi Lai, Jiaxing Pan, Yuejiao Gu, et al.
Science Bulletin
|
May 11, 2023
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Jing Gao, Lei Yang, Shumin Lei, et al.
Angewandte Chemie (International Ed. in English)
|
December 29, 2017
Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction
Shilin Xu, Angelo Aguilar, Tianfeng Xu, et al.
Journal of Medicinal Chemistry
|
March 10, 2023
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers
Zehui Zhou, Guizhen Zhou, Chuan Zhou, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry
|
June 28, 2019
Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction
Angelo Aguilar, Ke Zheng, Tianfeng Xu, et al.
Journal of Medicinal Chemistry
|
August 30, 2023
Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Journal of Medicinal Chemistry
|
June 29, 2023
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Journal of Medicinal Chemistry
|
January 10, 2024
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS<sup>G12D</sup>
Chuan Zhou, Zisheng Fan, Yuejiao Gu, et al.
Journal of Medicinal Chemistry
|
February 21, 2012
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant
Shaohua Chang, Lianwen Zhang, Shilin Xu, et al.
Journal of the American Chemical Society
|
June 4, 2026
Glycoengineered Host-Guest Nanoparticles Potentiate Alzheimer's Disease Therapy via Lesion-Specific Modulation of Tau Pathology
Yi Lai, Jiaxing Pan, Yuejiao Gu, et al.
Science Bulletin
|
May 11, 2023
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Jing Gao, Lei Yang, Shumin Lei, et al.
Angewandte Chemie (International Ed. in English)
|
December 29, 2017
Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction
Shilin Xu, Angelo Aguilar, Tianfeng Xu, et al.
Journal of Medicinal Chemistry
|
March 10, 2023
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers
Zehui Zhou, Guizhen Zhou, Chuan Zhou, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry
|
June 28, 2019
Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction
Angelo Aguilar, Ke Zheng, Tianfeng Xu, et al.
Journal of Medicinal Chemistry
|
August 30, 2023
Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Journal of Medicinal Chemistry
|
June 29, 2023
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
Page
of 6